Oral tranexamic acid seen as efficacious, safe vs IV, topical forms for THA
Results published in The Journal of Arthroplasty showed use of oral tranexamic acid during total hip arthroplasty was efficacious, safe and low cost compared with IV and topical tranexamic acid.
Researchers randomly assigned 180 patients undergoing total hip arthroplasty to receive tranexamic acid (TXA) either orally, through IV or topically. Researchers defined the primary outcome as the reduction in hemoglobin, and secondary outcomes included blood loss, transfusion rate, cost of TXA and adverse events.
Results showed no significant difference in mean reduction in hemoglobin level between the three groups. Researchers also found the three groups had no significant differences in total blood loss, transfusion rate, the number of units of packed red blood cells transfused and the length of hospital stay. Cost for TXA was lowest in the oral group at $70.56 compared with $489.40 in the IV group and $520.38 in the topical group. During the follow-up period, results showed no other adverse events, such as deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke or acute renal failure. Results showed one patient in the oral group reported being neither satisfied nor dissatisfied. – by Casey Tingle
Disclosure s : The researchers report no relevant financial disclosures.